← Top stories
Policy● Neutral for Indian equities
A Cancer Test Has Investors Betting Big. But Will Insurers Pay?
The brief
- An FDA panel backed Grail’s Galleri test
- Medicare coverage, which the business depends on, is far from guaranteed
- Zydus hits 52-week high, can the optimism continue?
- Zydus Life USFDA inspection at Ahmedabad plant concludes with 1 observation
- Zydus Lifesciences’ New Jersey office clears USFDA inspection with no observations